Clinical Web Archive

Sign in Subscribe

Oncology

Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.

Quick Take: VATS lobectomy for lung cancer delivers survival outcomes equivalent to open lobectomy, solidifying its role as a preferred surgical approach when technically feasible.

💡 Clinical Impact

Reinforces current practice by validating that minimally invasive VATS does not compromise long-term oncologic survival compared to open surgery.
Supports continued patient selection for VATS, leveraging its known benefits of reduced pain, shorter hospital stays, and quicker recovery without sacrificing efficacy.

📊 Evidence Breakdown

Evidence Grade: 9/10
Analysis: An individual patient data meta-analysis of randomized controlled trials confirms similar survival outcomes between VATS and open lobectomy for lung cancer, offering the highest level of evidence to support the non-inferiority of the minimally invasive approach.

🩺 Practice Recommendation

Continue to prioritize VATS lobectomy for lung cancer when technically feasible. This robust evidence supports its equivalent long-term survival while capitalizing on the established advantages of minimally invasive surgery.

View Original Research

Read next

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials.

Quick Take: Ovarian ablation or suppression significantly reduces breast cancer recurrence and improves survival, particularly in premenopausal women with hormone-sensitive disease. 💡 Clinical Impact * Mechanistic: Ovarian ablation/suppression directly lowers circulating estrogen levels, a critical driver for the growth of ER-positive breast cancers. * Clinical/Systemic: This intervention offers a robust, non-chemotherapy-based

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

This Phase III RCT robustly demonstrates improved CNS relapse-free survival with high-dose cytarabine consolidation in DLBCL, albeit with increased neurotoxicity. 💡 Clinical Impact * Mechanistic: High-dose cytarabine achieves superior cerebrospinal fluid penetration compared to standard intrathecal prophylaxis, effectively eradicating microscopic leptomeningeal disease. * Clinical/Systemic: This data necessitates a re-evaluation of current CNS

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.

CDK4/6 inhibitors with endocrine therapy unequivocally improve progression-free survival in HR+/HER2- advanced breast cancer. 💡 Clinical Impact * Mechanistic: This data solidifies the role of dual pathway inhibition (estrogen receptor and cell cycle progression) in overcoming endocrine resistance, a common obstacle in advanced disease. * Clinical/Systemic: Widespread adoption necessitates updated